Date: 2017-06-12
Type of information: Nomination
Compound:
Company: GlycoMimetics (USA - Md)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 12, 2017, GlycoMimetics announced the appointment of Patricia S. Andrews, chief executive officer and director of Boston Biomedical, to its Board of Directors. Ms. Andrews was named CEO of Boston Biomedical in April 2017. She joined the company in 2013 and was most recently its Executive Vice President and Chief Operating Officer, where she prepared for launching the company's first product, and guided the company's pipeline development. Previously, she was Executive Vice President and Chief Commercial Officer at Incyte, leading commercial operations for that company's launch of first-in-class, first-in-disease oncology product Jakafi®. Before that, she served in leadership positions at Pfizer, where her final role was Vice President and General Manager of the U.S. Oncology Business Unit, and at Marine Midland/HSBC, where she was Vice President in corporate finance. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University.
Financial terms:
Latest news:
Is general: Yes
